Scholarlink

Background <p>Breast cancer impacts nearly one-third of women globally during their lifetime, with the risk increasing in those exhibiting elevated gene expression linked to genetic polymorphisms. In Pakistan, breast cancer ranks among the top 20 leading causes of death, affecting one in every nine women.</p> Methods and results <p>Gene expression analysis was performed by quantifying mRNA levels of <i>CCND1</i>,<i> CDK4</i>, and <i>CDKN2B</i> genes using TaqMan probe-based reverse transcription quantitative PCR (RT-qPCR). In parallel, genomic DNA was extracted from breast tissue samples, and specific regions of the <i>CCND1</i>,<i> CDK4</i>,<i> CDKN2B</i>, and <i>TP53</i> genes were amplified to identify nucleotide variants. Relative to adjacent normal breast tissue, upregulation of <i>CCND1</i> and <i>CDK4</i> was observed in 77.78% and 66.67% of cases, respectively, whereas <i>CDKN2B</i> was downregulated in 88.89% of samples. Variant analysis of <i>CCND1</i> revealed three previously reported polymorphisms (rs55911137, rs3862792, rs9344). In <i>CDK4</i>, two novel missense mutations were identified at codons 97 (D97N) and 114 (A114T), in addition to two known intronic variants, rs78130877 and rs2069502, located in introns 3 and 4, respectively. Furthermore, a nonsense mutation was detected in TP53, involving a substitution at codon 169 that replaced methionine with a premature stop codon (AUG → UAG), potentially impairing protein structure and function.</p> Conclusion <p>The observed upregulation of <i>CCND1</i> and <i>CDK4</i>, along with the downregulation of <i>CDKN2B</i> and the presence of genetic mutations in these genes and <i>TP53</i>, may serve as significant biomarkers for breast cancer. These findings could aid in disease prognosis, inform treatment strategies, and support diagnostic efforts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Altered expression and mutations in cell cycle genes CCND1, CDK4, CDKN2B and TP53 are associated with Pakistani breast cancer patients

  • 期刊论文

  • 发表日期：

    2026年2月27日

查看全文
  • Wajeeha Tariq,
  • Ali Raza Awan,
  • Asim Khalid Mahmood,
  • Muhammad Wasim

摘要

Background

Breast cancer impacts nearly one-third of women globally during their lifetime, with the risk increasing in those exhibiting elevated gene expression linked to genetic polymorphisms. In Pakistan, breast cancer ranks among the top 20 leading causes of death, affecting one in every nine women.

Methods and results

Gene expression analysis was performed by quantifying mRNA levels of CCND1, CDK4, and CDKN2B genes using TaqMan probe-based reverse transcription quantitative PCR (RT-qPCR). In parallel, genomic DNA was extracted from breast tissue samples, and specific regions of the CCND1, CDK4, CDKN2B, and TP53 genes were amplified to identify nucleotide variants. Relative to adjacent normal breast tissue, upregulation of CCND1 and CDK4 was observed in 77.78% and 66.67% of cases, respectively, whereas CDKN2B was downregulated in 88.89% of samples. Variant analysis of CCND1 revealed three previously reported polymorphisms (rs55911137, rs3862792, rs9344). In CDK4, two novel missense mutations were identified at codons 97 (D97N) and 114 (A114T), in addition to two known intronic variants, rs78130877 and rs2069502, located in introns 3 and 4, respectively. Furthermore, a nonsense mutation was detected in TP53, involving a substitution at codon 169 that replaced methionine with a premature stop codon (AUG → UAG), potentially impairing protein structure and function.

Conclusion

The observed upregulation of CCND1 and CDK4, along with the downregulation of CDKN2B and the presence of genetic mutations in these genes and TP53, may serve as significant biomarkers for breast cancer. These findings could aid in disease prognosis, inform treatment strategies, and support diagnostic efforts.